03.01.2011 • NewsK+SRohm and HaasDow Chemical

K+S Sues Dow Chemical, Says Overpaid For Morton Salt

Fertilizer producer K+S sued Dow Chemical's Rohm & Haas unit, saying that it paid the company too much for its Morton Salt unit and is owed a refund.

Germany's K+S paid about $1.58 billion for the Morton brand in April 2009, just as Dow was closing on its more than $16 billion buyout of Rohm & Haas.
The buyout of Morton, founded in 1848, made K+S the world's largest salt producer.

In a filing with a U.S. District Court, K+S said the sales agreement stipulated that the final price for Morton would be raised or lowered after the deal closed.

Based on several financial metrics, the final closing price should have been $1.56 billion and Rohm & Haas owes K+S $14.6 million, plus interest, K+S said in the lawsuit.

Rohm has not yet been served with the reported suit, but believes it is "unnecessary and without merit," a spokesman for Dow said in an emailed statement.
Dow Chemical sold the Morton assets the same day it bought Rohm.

K+S also claims that Rohm & Haas did not disclose certain Canadian pension obligations. The German company said it is seeking C$19 million due to the alleged nondisclosure.

The case is K+S AG v. Rohm & Haas Co, U.S. District Court, Southern District of New York, No. 10-cv-9689.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.